Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1693840

	registered interest
	date	05/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cardiovascular Diseases: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent steps (a) her Department and (b) NHS England have taken to incentivise the integration of digital technologies into cardiovascular disease care pathways.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	17076
	answer	answer is ministerial correction date of answer 13/03/2024 answer text <p>The Government’s commitment to develop a national digital service to support the NHS Health Check was announced in the Health Reform speech on 8 March 2022, and forms a part of the Department’s plan for digital health and social care. The vision is to increase the flexibility and reach of the NHS Health Check through the creation of an innovative, accessible national digital service, delivered alongside local face-to-face offerings, that helps people understand and take action when engaging with their cardiovascular health. Whilst there isn't any specific policy development surrounding integrating digital technologies into care pathways, NHS England has developed an information guide that will help clarify the commissioning pathway. This will encourage the adoption of digital health technologies into the National Health Service, including those in cardiovascular diseases.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/03/2024 16:21:05 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1586 label Biography information for Adam Afriyie

1695458

	registered interest
	date	12/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Construction
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has approved the business case costings for the New Hospital Programme.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	18276
	answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>On 25 May 2023, the Government announced that the New Hospital Programme (NHP) is expected to represent over £20 billion of capital investment for the financial year 2030/31, and that there would be a rolling programme of investment in health infrastructure in the longer term. Future spending beyond this current spending review period will be subject to the usual spending review processes.</p><p>The NHP has developed a third version of its Programme Business Case (PBC) which includes costs for the programme’s future spend. This was approved by the Department’s Joint Investment Committee on 19 February 2024. Following this approval, the PBC will go through Government assurance processes in May 2024.</p><p> </p><p>Future spend will be confirmed through the usual processes of future spending reviews, and all funding allocations for specific schemes within the NHP will only be confirmed once the individual Full Business Cases have been reviewed and agreed by ministers.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/03/2024 15:18:09 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4658 label Biography information for Alex Sobel

1701859

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bile Duct Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve the treatment of Cholangiocarcinoma cancers; and whether a proportion of the additional funding allocated to her Department in the Spring Budget 2024 will be used to treat Cholangiocarcinoma cancers.
	tabling member constituency	Wirral South
	tabling member printed	Alison McGovern
	uin	22296
	answer	answer is ministerial correction date of answer 23/04/2024 answer text <p>Cancer is being diagnosed at an earlier stage, more often, with survival rates improving across almost all types of cancer, and the National Health Service has been seeing and treating record numbers of cancer patients over the last two years. Improving early diagnosis of cancer, including cholangiocarcinoma cancers, is a priority for the NHS. The NHS has an ambition to diagnose 75% of cancers at stage 1 or 2 by 2028, which will help tens of thousands of people live for longer.</p><p>Although funding for treatment isn’t allocated for specific cancers, the Government has provided significant additional funding to the NHS and adult social care in England. Measures introduced at the Spring Budget will protect levels of funding for the NHS in England in real terms in 2024/25, by providing an extra £2.5 billion for 2024/25, meaning a total budget of £164.9 billion.</p><p>While this additional spending is needed, the Government recognises that more money cannot always be the answer to improving outcomes for patients. Alongside the £2.5 billion of extra funding for day-to-day activities, the Government will invest £3.4 billion to reform the way the NHS works. This funding will significantly reduce the 13 million hours of time doctors spend on poor IT, freeing up significant capacity, and revolutionising treatment for a range of illnesses such as cancer and strokes. This will double the investment in technological and digital transformation in the NHS in England, and turn the NHS into one of the most digitally enabled, productive healthcare systems in the world.</p><p>On 14 August 2023, the Government published the Major Conditions Strategy’s Case for Change and Our Strategic Framework, which sets out our approach to making the choices over the next five years that will deliver the most value when facing the health challenges of today and of the decades ahead, including for cancer. It will look at the treatment and prevention of cancer, covering the patient pathway. The strategy will look at a wide range of interventions and enablers, to improve outcomes and experience for cancer patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/04/2024 13:42:02 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4083 label Biography information for Alison McGovern

1701863

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what funding has her Department allocated to provide recovery spaces for families of cancer treatment patients.
	tabling member constituency	Wirral South
	tabling member printed	Alison McGovern
	uin	22297
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer treatment, which encompasses recovery spaces. Additionally, and as outlined in the 2024/25 NHS England Planning Guidance, NHS England are providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.</p><p>The Department and NHS England meet regularly to discuss a wide range of issues regarding cancer. The Department's ministers and officials also frequently meet with key stakeholders within the cancer community, including discussions on support for patients and their families. As stated in the NHS Long Term Plan for Cancer, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information, and support. NHS England provides personalised cancer care and support plans, to support both patients and their families at all stages of their cancer journey. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support. NHS England estimates that approximately 80% of cancer multidisciplinary teams are now offering Personalised Care and Support Planning, ensuring physical, practical, emotional, and social needs are identified and addressed at all stages of the cancer pathway. Additionally, Personalised Stratified Follow Up pathways, which adapt care to the needs of individual patients after cancer treatment, are being rolled out by cancer multi-disciplinary teams, and are required for at least eight cancer types by 2023/24.</p><p>General practice surgeries also conduct cancer care reviews at regular intervals after cancer diagnosis, to offer support with any needs patients may have. This includes providing access to other specialist-led services who work alongside patients’ medical teams, to support patients and their families, such as counsellors, rehabilitation specialists, or social prescribers, who can connect you to community groups or services for more support. This is part of NHS England’s drive to universal personalised care that will see at least 2.5 million people benefiting from personalised care by 2023/24.</p><p>NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities in England are met, including for cancer patients. NHS England provide access to a personal health budget, which is an amount of NHS money that is allocated to support the health and wellbeing needs of a patient if eligible. More information is available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/" target="_blank">https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22298 question first answered 22/04/2024 11:02:18 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4083 label Biography information for Alison McGovern

1701890

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions her Department has had with cancer treatment support groups on the use of direct funds to support patients and their families.
	tabling member constituency	Wirral South
	tabling member printed	Alison McGovern
	uin	22298
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer treatment, which encompasses recovery spaces. Additionally, and as outlined in the 2024/25 NHS England Planning Guidance, NHS England are providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.</p><p>The Department and NHS England meet regularly to discuss a wide range of issues regarding cancer. The Department's ministers and officials also frequently meet with key stakeholders within the cancer community, including discussions on support for patients and their families. As stated in the NHS Long Term Plan for Cancer, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information, and support. NHS England provides personalised cancer care and support plans, to support both patients and their families at all stages of their cancer journey. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support. NHS England estimates that approximately 80% of cancer multidisciplinary teams are now offering Personalised Care and Support Planning, ensuring physical, practical, emotional, and social needs are identified and addressed at all stages of the cancer pathway. Additionally, Personalised Stratified Follow Up pathways, which adapt care to the needs of individual patients after cancer treatment, are being rolled out by cancer multi-disciplinary teams, and are required for at least eight cancer types by 2023/24.</p><p>General practice surgeries also conduct cancer care reviews at regular intervals after cancer diagnosis, to offer support with any needs patients may have. This includes providing access to other specialist-led services who work alongside patients’ medical teams, to support patients and their families, such as counsellors, rehabilitation specialists, or social prescribers, who can connect you to community groups or services for more support. This is part of NHS England’s drive to universal personalised care that will see at least 2.5 million people benefiting from personalised care by 2023/24.</p><p>NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities in England are met, including for cancer patients. NHS England provide access to a personal health budget, which is an amount of NHS money that is allocated to support the health and wellbeing needs of a patient if eligible. More information is available at the following link:</p><p><a href="https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/" target="_blank">https://www.nhs.uk/nhs-services/help-with-health-costs/what-is-a-personal-health-budget/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22297 question first answered 22/04/2024 11:02:18 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4083 label Biography information for Alison McGovern

1713251

	registered interest
	date	23/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Brain: Tumours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NHS England plans to provide dendric cell therapy for glioma.
	tabling member constituency	Mid Bedfordshire
	tabling member printed	Alistair Strathern
	uin	23351
	answer	answer is ministerial correction date of answer 29/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) evaluates all new licensed medicines, including medicines for glioma, to determine whether they represent a clinically and cost-effective use of resources. The NICE aims to publish guidance on new medicines as close as possible to licensing. Any medicine for glioma, recommended in draft NICE guidance, will be eligible for funding through the Cancer Drugs Fund from the point a positive draft guidance is published, in line with the standard arrangements for cancer medicines.</p><p>On 24 April 2024, the NICE published draft guidance recommending a new treatment for glioma in children and young people that will be available to eligible patients once supply of the treatment is available.</p><p>There are currently no licensed dendritic cell therapies for glioma. A number of dendritic cell therapies are in development for the treatment of glioma, and any new licensed and NICE recommended treatments would be funded by NHS England, in line with NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23350 question first answered 29/04/2024 11:21:40 answering member 4044 label Biography information for Andrew Stephenson previous answer version 30800 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	5000 label Biography information for Alistair Strathern

1713250

	registered interest
	date	23/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Brain: Tumours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the availability of treatment for glioma on the NHS.
	tabling member constituency	Mid Bedfordshire
	tabling member printed	Alistair Strathern
	uin	23350
	answer	answer is ministerial correction date of answer 29/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) evaluates all new licensed medicines, including medicines for glioma, to determine whether they represent a clinically and cost-effective use of resources. The NICE aims to publish guidance on new medicines as close as possible to licensing. Any medicine for glioma, recommended in draft NICE guidance, will be eligible for funding through the Cancer Drugs Fund from the point a positive draft guidance is published, in line with the standard arrangements for cancer medicines.</p><p>On 24 April 2024, the NICE published draft guidance recommending a new treatment for glioma in children and young people that will be available to eligible patients once supply of the treatment is available.</p><p>There are currently no licensed dendritic cell therapies for glioma. A number of dendritic cell therapies are in development for the treatment of glioma, and any new licensed and NICE recommended treatments would be funded by NHS England, in line with NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23351 question first answered 29/04/2024 11:21:40 answering member 4044 label Biography information for Andrew Stephenson previous answer version 30798 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	5000 label Biography information for Alistair Strathern

1701903

	registered interest
	date	17/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support effective routes to market for precision medicines for (a) motor neurone disease and (b) other rare diseases in the UK.
	tabling member constituency	Northampton South
	tabling member printed	Andrew Lewer
	uin	22376
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Should the Medicines and Healthcare products Regulatory Agency (MHRA) receive a marketing authorisation application (MAA) or applications, the MHRA will consider the drug with regards to quality, safety, and efficacy. The MHRA has procedures in place to consider drugs as part of an accelerated pathway. This is possible as part of national access collaboration, and international recognition. The MHRA would be able to consider motor neurone disease and other rare disease treatment products, under any of the procedures for the benefit of patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 16:29:38 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4659 label Biography information for Andrew Lewer

1700047

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Alzheimer's Disease: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she has taken to support research and development of the ACI-24 Alzheimer’s disease treatment.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	20911
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). The Government is strongly committed to supporting research into dementia, including Alzheimer’s disease treatment, and has committed to doubling funding for dementia research to £160 million per year, by the end of 2024/25.</p><p> </p><p>In addition, the NIHR’s infrastructure provides funding for clinical expertise, specialist facilities, the workforce, and support services, which underpin research across a range of clinical areas, including Alzheimer’s disease treatments. Specifically, the NIHR’s Oxford Health Clinical Research Facility (CRF) has enabled the delivery of the ABATE part 1 trial, which seeks to study the effects of the ACI-24 vaccine in those diagnosed with early-stage Alzheimer’s disease. The NIHR’s CRFs are purpose-built facilities for early-phase, experimental medicine, and supporting life science companies throughout the research process from study, design, data collection, and trial management.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:07:46 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1447 label Biography information for Andrew Rosindell

1697942

	registered interest
	date	21/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sickle Cell Diseases: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she has taken to support (a) research into and (b) treatment of sickle cell disease in (i) England and (ii) Romford constituency.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	19821
	answer	answer is ministerial correction date of answer 28/03/2024 answer text <p>We’re working hard to support research, and provide the best possible care to those living with sickle cell disease (SCD) across the country. The Department funds health and care research through the National Institute for Health and Care Research (NIHR). Over the past five financial years, the NIHR has invested more than £8 million in funding and support for SCD research.</p><p>NHS Blood and Transplant (NHSBT) is the largest provider of apheresis services, a blood transfusion used to treat SCD. NHSBT will be delivering projects over the next 12 months that will increase both nursing capacity and the physical space in which apheresis occurs. We are also working to increase Ro subtype blood donation numbers, the blood type used to treat SCD, identify opportunities to improve clinical pathways, and deliver world-leading treatments, such as the new blood matching genetic test announced by NHS England earlier this year, which will reduce the risk of side effects and offer more personalised care.</p><p>NHS England’s Chief Executive Officer has committed to improving the treatment and outcomes of patients with SCD, and has commissioned a Sickle Cell Pathway Quality Improvement work package. A quality improvement review of existing processes has led to a range of improvements including awareness, education, and training of both patients and professionals.</p><p>The National Healthcare Inequalities Improvement Programme (HiQiP) has recently introduced a number of initiatives as part of the wider aim of tackling inequalities for people living with SCD. This includes: piloting of urgent and emergency department bypass units in London and Manchester, which will ensure people with SCD with an uncomplicated vaso-occlusive crisis are assessed and given pain relief in a timely manner; the provision of a credit card sized Sickle Cell Alert Card to all people with SCD, to alert medical and clinical staff that the carrier is a registered SCD patient and that they should be managed as a medical emergency; a London wide commissioning for the design and upload of a patient care record onto an interoperable digital platform which, when fully operational, will give clinicians and medical personnel in different regions access to a patient’s personalised care and analgesia record, removing ambiguity on effective treatment; and several products to support the above, including a communications campaign to raise awareness of existing NHS England arrangements to support people with SCD to save money on the costs of regular prescriptions, as well as the Can you tell it's Sickle Cell campaign and an e-learning module, both from NHS England. Further information on the Can you tell it's Sickle Cell campaign and the e-learning module is available respectively, at the following links:</p><p><a href="https://www.england.nhs.uk/2022/06/nhs-launches-lifesaving-sickle-cell-campaign/" target="_blank">https://www.england.nhs.uk/2022/06/nhs-launches-lifesaving-sickle-cell-campaign/</a></p><p><a href="https://www.e-lfh.org.uk/programmes/health-inequalities/" target="_blank">https://www.e-lfh.org.uk/programmes/health-inequalities/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 28/03/2024 13:32:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1447 label Biography information for Andrew Rosindell